Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
ConditionT-Acute Lymphoblastic Leukemia
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorZhejiang University
About this trial
A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-ALL
Eligibility criteria
Qualifiers
1. According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphocytic Leukemia (2020. v1), patients diagnosed as CD5+T-ALL;
No CR after standard chemotherapy;
The first induction reaches CR, but CR ≤ 12 months;
Patients with r/r CD5+T-ALL have not responded to the first or multiple remedial treatments;
Disqualifiers
1.Patients with the history of epilepsy or other CNS disease;
2. Patients with prolonged QT interval time or severe heart disease;
3. Active infection of hepatitis B virus, C virus or hepatitis E virus;
4. Active infection with no cure;
Trial design
Treatments tested in this trial
- CD5 CAR T-cells
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Zhejiang University
Lead sponsor
Yake Biotechnology Ltd.
Collaborator
Source ClinicalTrials.gov